173 related articles for article (PubMed ID: 30573241)
1. Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier.
Cristallini C; Barbani N; Ventrelli L; Summa C; Filippi S; Capelôa T; Vitale E; Albera C; Messore B; Giachino C
Mater Sci Eng C Mater Biol Appl; 2019 Feb; 95():19-28. PubMed ID: 30573241
[TBL] [Abstract][Full Text] [Related]
2. Inhalable DNase I microparticles engineered with biologically active excipients.
Osman R; Al Jamal KT; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O
Pulm Pharmacol Ther; 2013 Dec; 26(6):700-9. PubMed ID: 23933140
[TBL] [Abstract][Full Text] [Related]
3. Model of mucociliary clearance in cystic fibrosis lungs.
Kurbatova P; Bessonov N; Volpert V; Tiddens HA; Cornu C; Nony P; Caudri D;
J Theor Biol; 2015 May; 372():81-8. PubMed ID: 25746843
[TBL] [Abstract][Full Text] [Related]
4. Mucus, phlegm, and sputum in cystic fibrosis.
Rubin BK
Respir Care; 2009 Jun; 54(6):726-32; discussion 732. PubMed ID: 19467160
[TBL] [Abstract][Full Text] [Related]
5. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
[TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
[TBL] [Abstract][Full Text] [Related]
7. Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH.
Hill DB; Long RF; Kissner WJ; Atieh E; Garbarine IC; Markovetz MR; Fontana NC; Christy M; Habibpour M; Tarran R; Forest MG; Boucher RC; Button B
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361244
[TBL] [Abstract][Full Text] [Related]
8. Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.
Stigliani M; Manniello MD; Zegarra-Moran O; Galietta L; Minicucci L; Casciaro R; Garofalo E; Incarnato L; Aquino RP; Del Gaudio P; Russo P
J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):337-45. PubMed ID: 26741302
[TBL] [Abstract][Full Text] [Related]
9. Assisting PNA transport through cystic fibrosis human airway epithelia with biodegradable hybrid lipid-polymer nanoparticles.
Comegna M; Conte G; Falanga AP; Marzano M; Cernera G; Di Lullo AM; Amato F; Borbone N; D'Errico S; Ungaro F; d'Angelo I; Oliviero G; Castaldo G
Sci Rep; 2021 Mar; 11(1):6393. PubMed ID: 33737583
[TBL] [Abstract][Full Text] [Related]
10. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
[TBL] [Abstract][Full Text] [Related]
11. Pro-inflammatory effect of cystic fibrosis sputum microparticles in the murine lung.
Porro C; Di Gioia S; Trotta T; Lepore S; Panaro MA; Battaglino A; Ratclif L; Castellani S; Bufo P; Martinez MC; Conese M
J Cyst Fibros; 2013 Dec; 12(6):721-8. PubMed ID: 23567201
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate loaded gellan gum microparticles for drug delivery.
Dhanka M; Shetty C; Srivastava R
Int J Biol Macromol; 2018 Apr; 110():346-356. PubMed ID: 29223759
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic options for hydrating airway mucus in cystic fibrosis.
Tildy BE; Rogers DF
Pharmacology; 2015; 95(3-4):117-32. PubMed ID: 25823699
[TBL] [Abstract][Full Text] [Related]
14. Inhaled Biologicals for the Treatment of Cystic Fibrosis.
Sala V; Murabito A; Ghigo A
Recent Pat Inflamm Allergy Drug Discov; 2019; 13(1):19-26. PubMed ID: 30318010
[TBL] [Abstract][Full Text] [Related]
15. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels.
Yuan S; Hollinger M; Lachowicz-Scroggins ME; Kerr SC; Dunican EM; Daniel BM; Ghosh S; Erzurum SC; Willard B; Hazen SL; Huang X; Carrington SD; Oscarson S; Fahy JV
Sci Transl Med; 2015 Feb; 7(276):276ra27. PubMed ID: 25717100
[TBL] [Abstract][Full Text] [Related]
16. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Mall MA
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S177-85. PubMed ID: 27115954
[TBL] [Abstract][Full Text] [Related]
17. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Nafee N; Forier K; Braeckmans K; Schneider M
Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.
Tang BC; Dawson M; Lai SK; Wang YY; Suk JS; Yang M; Zeitlin P; Boyle MP; Fu J; Hanes J
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19268-73. PubMed ID: 19901335
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the Spreading Behavior on Pulmonary Mucus Mimicking Subphase via Catanionic Surfactant Solutions: Toward Effective Drug Delivery through the Lungs.
Alp G; Aydogan N
Mol Pharm; 2018 Mar; 15(3):1361-1370. PubMed ID: 29436839
[TBL] [Abstract][Full Text] [Related]
20. Mucus concentration-dependent biophysical abnormalities unify submucosal gland and superficial airway dysfunction in cystic fibrosis.
Kato T; Radicioni G; Papanikolas MJ; Stoychev GV; Markovetz MR; Aoki K; Porterfield M; Okuda K; Barbosa Cardenas SM; Gilmore RC; Morrison CB; Ehre C; Burns KA; White KK; Brennan TA; Goodell HP; Thacker H; Loznev HT; Forsberg LJ; Nagase T; Rubinstein M; Randell SH; Tiemeyer M; Hill DB; Kesimer M; O'Neal WK; Ballard ST; Freeman R; Button B; Boucher RC
Sci Adv; 2022 Apr; 8(13):eabm9718. PubMed ID: 35363522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
